drugset
Drugs / Z160
last change Nov 2013 re-read 3 minutes ago

Z160

also known as MK-6721 · NMED-160 · NP-118809

Small molecule targets CACNA1B via inhibition

Developed for
postherpetic neuralgia · radiculopathy
Investigated by
Zalicus

Trials 2

today NCT01757873 · Ph 2 NCT01655849 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01757873 Dec 2012 → Nov 2013 postherpetic neuralgia Zalicus Completed No outcome recorded
Phase 2 NCT01655849 Aug 2012 → Oct 2013 radiculopathy Zalicus Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as z160 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01655849 ↗
1

NCT01757873 ↗
Known as MK-6721 ChEMBL registry synonym — accepted as the source's own label CHEMBL604710 ↗
Known as NMED-160 ChEMBL registry synonym — accepted as the source's own label CHEMBL604710 ↗
Known as NP-118809 ChEMBL registry synonym — accepted as the source's own label CHEMBL604710 ↗
Action Inhibit “Voltage-gated N-type calcium channel alpha-1B subunit blocker” CHEMBL604710 ↗
Modality Small molecule — CHEMBL604710 ↗
Target CACNA1B “Voltage-gated N-type calcium channel alpha-1B subunit blocker” CHEMBL604710 ↗